Your Ad Here
How to make humans

Compilation of free information about human parts, their function, assembly,  repair, and maintenance

Erythropoietin

erythropoietin
Identifiers
Symbol EPO
Entrez 2056
HUGO 3415
OMIM 133170
RefSeq NM_000799
UniProt P01588
Other data
Locus Chr. 7 q21

Erythropoietin (IPA pronunciation: [ɪˌɹɪθ.ɹoˈpo.ɪ.tɪn], alternative pronunciations: [ɪˌrɪθroʊˈpɔɪtn, əˌrɪθroʊ-, əˌriθroʊ-]) or EPO is a glycoprotein hormone that is a cytokine for erythrocyte (red blood cell) precursors in the bone marrow. Also called hematopoietin or hemopoietin, it is produced by the kidney, and is the hormone regulating red blood cell production.

Uses

Erythropoietin is available as a therapeutic agent produced by recombinant DNA technology in mammalian cell culture. It is used in treating anemia resulting from chronic renal failure or from cancer chemotherapy.

Anemia due to renal failure

In patients who have chronic renal failure, iron should be given with erythropoietin.[1]

Critically ill patients

In a randomized controlled trial, erythropoietin insignificantly reduced mortality among critically ill patients. If larger studies find a statistically significant result and the same event rates, 35 patients would need treatment to prevent one death (number needed to treat is 35)[2] Although the editorial accompanying the trial concluded this benefit was insufficient, less patients would require this treatment to save one life than the number of patients treated with other commonly accepted interventions (such as primary prevention of coronary disease in patients with hypertriglyceridemia. If the benefit must be weighed against the 5% absolute increase in thrombosis.

Blood doping

It has a history of usage as a blood doping agent in endurance sports such as bicycle racing, triathlons and marathon running.

Adverse effects

Erythropoietin is associated with an increased risk of adverse cardiovascular complications in patients with kidney disease if it is used to increase hemoglobin levels above 13.0 g/dl.[3]

Safety advisories in anemic cancer patients

Amgen sent a "dear doctor" letter in January, 2007, that highlighted results from a recent anemia of cancer trial, and warned doctors to consider use in that off-label indication with caution.

Amgen advised the United States FDA as to the results of the DAHANCA 10 clinical trial. The DAHANCA 10 data monitoring committee found that 3-year loco-regional control in subjects treated with Aranesp was significantly worse than for those not receiving Aranesp (p=0.01).

In response to these advisories, the FDA released a Public Health Advisory[4] on March 9, 2007, and a clinical alert[5] for doctors on February 16, 2007, about the use of erythropoeisis-stimulating agents such as epogen and darbepoetin. The advisory recommended caution in using these agents in cancer patients receiving chemotherapy or off chemotherapy, and indicated a lack of clinical evidence to support improvements in quality of life or transfusion requirements in these settings.

In addition, on March 9, 2007, drug manufacturers agreed to new black box warnings about the safety of these drugs.

On March 22, 2007, a congressional inquiry into the safety of erythropoeitic growth factors was reported in the news media. Manufacturers were asked to suspend drug rebate programs for physicians and to also suspend marketing the drugs to patients.

See also

Additional images

EPO hematopoiesis

JAK-STAT signaling pathway

EPO structure

Epo blotting

EPO sales

References

  1. ^ Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE (1996). "A randomized controlled study of iron supplementation in patients treated with erythropoietin". Kidney Int. 50 (5): 1694-9. PMID 8914038. 
  2. ^ Howard L. Corwin et al., “Efficacy and Safety of Epoetin Alfa in Critically Ill Patients,” N Engl J Med 357, no. 10 (September 6, 2007): 965-976, http://content.nejm.org/cgi/content/abstract/357/10/965 (accessed September 6, 2007).
  3. ^ Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A (2006). "Normalization of hemoglobin level in patients with chronic kidney disease and anemia". N. Engl. J. Med. 355 (20): 2071-84. DOI:10.1056/NEJMoa062276. PMID 17108342. 
  4. ^ FDA Public Health Advisory: Erythropoiesis-Stimulating Agents (ESAs): Epoetin alfa (marketed as Procrit, Epogen), Darbepoetin alfa (marketed as Aranesp). Retrieved on 2007-06-05.
  5. ^ Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA). Retrieved on 2007-06-05.

External links

The content of this section is licensed under the GNU Free Documentation License (local copy). It uses material from the Wikipedia article "Erythropoietin" modified September 15, 2007 with previous authors listed in its history.

Your Ad Here
Share on Facebook Delicious Bookmark this on Delicious